Amneal Pharmaceuticals (AMRX) 10-Q 8 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	Apr. 30, 2024
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-38485
Entity Registrant Name	Amneal Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	93-4225266
Entity Address, Address Line One	400 Crossing Boulevard,
Entity Address, City or Town	Bridgewater
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08807
City Area Code	908
Local Phone Number	947-3120
Title of 12(b) Security	Class A Common Stock, par value $0.01 per share
Trading Symbol	AMRX
Security Exchange Name	NASDAQ
Entity Current Reporting	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		308,651,373
Entity Central Index Key	0001723128
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 659,191	$ 557,540
Cost of goods sold	421,131	379,354
Gross profit	238,060	178,186
Selling, general and administrative	112,595	102,096
Research and development	39,298	38,690
Intellectual property legal development expenses	984	1,644
Restructuring and other charges	1,470	510
Change in fair value of contingent consideration	100	2,457
Charges (credit) related to legal matters, net	94,359	(436)
Other operating income	0	(1,224)
Operating (loss) income	(10,746)	34,449
Other (expense) income:
Interest expense, net	(65,703)	(49,315)
Foreign exchange (loss) gain, net	(1,197)	1,901
Increase in tax receivable agreement liability	(1,948)	(826)
Other income, net	4,072	4,365
Total other expense, net	(64,776)	(43,875)
Loss before income taxes	(75,522)	(9,426)
Provision for income taxes	6,156	668
Net loss	(81,678)	(10,094)
Less: Net (income) loss attributable to non-controlling interests	(9,965)	3,151
Net loss attributable to Amneal Pharmaceuticals, Inc.	$ (91,643)	$ (6,943)
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.30)	$ (0.05)
Diluted (in dollars per share)	$ (0.30)	$ (0.05)
Weighted-average common shares outstanding:
Basic (in shares)	307,279	152,109
Diluted (in shares)	307,279	152,109

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Other Comprehensive Income [Abstract]
Net (loss) income	$ (81,678)	$ (10,094)
Less: Net (income) loss attributable to non-controlling interests	(9,965)	3,151
Net loss attributable to Amneal Pharmaceuticals, Inc.	(91,643)	(6,943)
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period	(390)	1,797
Unrealized gain (loss) on cash flow hedge, net of tax of $0	15,543	(14,270)
Reclassification of cash flow hedge to earnings, net of tax of $0	(6,515)	0
Less: Other comprehensive loss attributable to non-controlling interests	0	6,236
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	8,638	(6,237)
Comprehensive loss attributable to Amneal Pharmaceuticals, Inc.	$ (83,005)	$ (13,180)

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on cash flow hedge, net of tax	$ 0	$ 0
Reclassification of cash flow hedge to earnings, net of tax	$ 0	$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 46,520	$ 91,542
Restricted cash	5,097	7,565
Inventories	570,653	581,384
Prepaid expenses and other current assets	87,298	82,685
Total current assets	1,380,044	1,377,863
Property, plant and equipment, net	439,815	447,574
Goodwill	598,549	598,629
Intangible assets, net	859,272	890,423
Other assets	73,747	55,517
Total assets	3,456,397	3,472,569
Current liabilities:
Current portion of liabilities for legal matters	30,130	76,988
Revolving credit facility	179,000	179,000
Current portion of long-term debt, net	33,660	34,125
Total current liabilities	834,388	846,595
Long-term debt, net	2,377,707	2,386,004
Note payable - related party	41,893	41,447
Liabilities for legal matters - long term	85,479	316
Total long-term liabilities	2,638,616	2,564,670
Commitments and contingencies (Notes 4 and 17)
Redeemable non-controlling interests	47,022	41,293
Stockholders' (Deficiency) Equity
Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	538,720	539,240
Stockholders' accumulated deficit	(581,819)	(490,176)
Accumulated other comprehensive loss	(23,711)	(32,349)
Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity	(63,724)	19,781
Non-controlling interests	95	230
Total stockholders' (deficiency) equity	(63,629)	20,011
Total liabilities and stockholders' (deficiency) equity	3,456,397	3,472,569
Related Party
Current assets:
Trade accounts receivable, net	1,521	955
Operating lease right-of-use assets	12,468	12,954
Current liabilities:
Accounts payable and accrued expenses	17,075	7,321
Current portion of operating lease liabilities - related party	3,192	2,825
Operating lease liabilities	11,969	12,787
Other long-term liabilities	11,394	11,776
Nonrelated Party
Current assets:
Trade accounts receivable, net	668,955	613,732
Operating lease right-of-use assets	32,970	30,329
Financing lease right-of-use assets	59,532	59,280
Current liabilities:
Accounts payable and accrued expenses	558,518	534,662
Current portion of operating lease liabilities	9,508	9,207
Current portion of financing lease liabilities	3,305	2,467
Operating lease liabilities	26,786	24,095
Financing lease liabilities	58,809	58,566
Other long-term liabilities	24,579	29,679
Common Class A
Stockholders' (Deficiency) Equity
Common stock	3,086	3,066
Common Class B
Stockholders' (Deficiency) Equity
Common stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Common Class A
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	900,000,000	900,000,000
Common stock, shares issued (in shares)	308,623,000	306,565,000
Common Class B
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	0	0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net (loss) income	$ (81,678)	$ (10,094)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	55,528	58,150
Unrealized foreign currency loss (gain)	1,511	(1,987)
Amortization of debt issuance costs and discount	288	2,058
Intangible asset impairment charges	920	0
Change in fair value of contingent consideration	100	2,457
Stock-based compensation	6,722	7,596
Inventory provision	22,923	25,204
Other operating charges and credits, net	1,250	2,047
Changes in assets and liabilities:
Trade accounts receivable, net	(55,173)	195,970
Inventories	(12,200)	(22,508)
Prepaid expenses, other current assets and other assets	(11,708)	29,160
Related party receivables	(562)	470
Accounts payable, accrued expenses and other liabilities	62,174	(150,483)
Related party payables	5,495	1,672
Net cash (used in) provided by operating activities	(4,410)	139,712
Cash flows from investing activities:
Purchases of property, plant and equipment	(9,198)	(9,688)
Acquisition of intangible assets	(9,700)	(338)
Deposits for future acquisition of property, plant and equipment	(862)	(1,711)
Net cash used in investing activities	(19,760)	(11,737)
Cash flows from financing activities:
Payments of principal on debt, revolving credit facilities, financing leases and other	(63,377)	(72,659)
Borrowings on revolving credit facilities	48,000	80,000
Proceeds from exercise of stock options	28	0
Employee payroll tax withholding on restricted stock unit vesting	(7,212)	(2,022)
Tax distributions to non-controlling interests	(594)	(18,219)
Net cash used in financing activities	(23,155)	(12,900)
Effect of foreign exchange rate on cash	(165)	767
Net (decrease) increase in cash, cash equivalents, and restricted cash	(47,490)	115,842
Cash, cash equivalents, and restricted cash - beginning of period	99,107	35,227
Cash, cash equivalents, and restricted cash - end of period	51,617	151,069
Cash and cash equivalents - end of period	46,520	144,674
Restricted cash - end of period	5,097	6,395
Cash, cash equivalents, and restricted cash - end of period	51,617	151,069
Supplemental disclosure of cash flow information:
Cash paid for interest	64,514	41,066
Cash (paid) received, net for income taxes	(4,567)	3,421
Supplemental disclosure of non-cash investing and financing activity:
Tax distributions to non-controlling interests	$ 3,777	$ 11,548

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock Common Class A	Common Stock Old PubCo, Common Class A	Common Stock Old PubCo, Common Class B	Additional Paid-in Capital	Stockholders' Accumulated Deficit	Accumulated Other Comprehensive Income	Non- Controlling Interests
Shares beginning balance (in shares) at Dec. 31, 2022			151,490	152,117
Stockholders' equity beginning balance at Dec. 31, 2022	$ 183,979		$ 1,514	$ 1,522	$ 691,629	$ (406,183)	$ 9,939	$ (114,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(15,631)					(6,943)		(8,688)
Foreign currency translation adjustments	1,797						898	899
Stock-based compensation	7,596				7,596
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)			1,831
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(1,995)		$ 18		1,497		62	(3,572)
Unrealized gain (loss) on cash flow hedge, net of tax	(14,270)						(7,135)	(7,135)
Tax distributions, net	(26,808)							(26,808)
Reclassification of cash flow hedge to earnings, net of tax of $0	0
Shares ending balance (in shares) at Mar. 31, 2023			153,321	152,117
Stockholders' equity ending balance at Mar. 31, 2023	134,668		$ 1,532	$ 1,522	700,722	(413,126)	3,764	(159,746)
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2022	24,949
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	5,537
Tax distributions, net	(2,959)
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2023	27,527
Shares beginning balance (in shares) at Dec. 31, 2023		306,565
Stockholders' equity beginning balance at Dec. 31, 2023	20,011	$ 3,066			539,240	(490,176)	(32,349)	230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(91,778)					(91,643)		(135)
Foreign currency translation adjustments	(390)						(390)
Stock-based compensation	6,722				6,722
Exercise of stock options (in shares)		10
Exercise of stock options	28				28
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)		2,048
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(7,250)	$ 20			(7,270)
Unrealized gain (loss) on cash flow hedge, net of tax	15,543						15,543
Reclassification of cash flow hedge to earnings, net of tax of $0	(6,515)						(6,515)
Shares ending balance (in shares) at Mar. 31, 2024		308,623
Stockholders' equity ending balance at Mar. 31, 2024	(63,629)	$ 3,086			$ 538,720	$ (581,819)	$ (23,711)	$ 95
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2023	41,293
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	10,100
Tax distributions, net	(4,371)
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2024	$ 47,022

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) (Parenthetical)	3 Months Ended
	Mar. 31, 2024 USD ($)
Statement of Stockholders' Equity [Abstract]
Unrealized gain (loss) on cash flow hedge, net of tax	$ 0
Reclassification of cash flow hedge to earnings, net of tax	$ 0

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, and biosimilars in our Generics segment and specialty branded pharmaceuticals. The Company operates principally in the United States (“U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company whose principal assets are 100% of the common units of Amneal Pharmaceuticals, LLC (“Amneal”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP. Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2023 Annual Report on Form 10-K. Use of Estimates The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates. Reclassification The prior period balance related to the TRA (as defined in Note 5. Income Taxes ) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss. The prior period balance related to long-term liabilities for legal matters of $0.3 million, formerly included in other long-term liabilities as of December 31, 2023, has been reclassified to the balance sheet caption “liabilities for legal matters - long term” to conform to the current period presentation in the consolidated balance sheets. This reclassification did not impact total long-term liabilities or total liabilities. Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time. License Agreements Refer to Note 4. Alliance and Collaboration for further information related to revenue recognition associated with license agreements. Concentration of Revenue The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue: Three Months Ended March 31, 2024 2023 Customer A 21 % 22 % Customer B 15 % 14 % Customer C 23 % 20 % Customer D 10 % 9 % Disaggregated Revenue The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands): Three Months Ended March 31, 2024 2023 Generics Anti-infective $ 6,110 $ 5,174 Hormonal / allergy 107,714 104,851 Antiviral 3,866 25,474 Central nervous system 109,456 84,582 Cardiovascular system 45,878 32,503 Gastroenterology 18,197 14,364 Oncology 38,533 10,578 Metabolic disease / endocrine 11,185 9,265 Respiratory 11,136 12,815 Dermatology 18,975 18,004 Other therapeutic classes 18,523 25,895 International and other 1,721 301 Total Generics net revenue 391,294 343,806 Specialty Hormonal / allergy 29,375 24,763 Central nervous system 66,276 60,139 License agreement (1) 4,479 — Other therapeutic classes 5,104 6,776 Total Specialty net revenue 105,234 91,678 AvKARE Distribution 109,713 83,230 Government label 34,952 24,516 Institutional 10,858 8,862 Other 7,140 5,448 Total AvKARE net revenue 162,663 122,056 Total net revenue $ 659,191 $ 557,540 (1) Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement. A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands): Contract Cash Discount Accrued Accrued Balance at December 31, 2023 $ 559,334 $ 23,892 $ 136,486 $ 90,690 Provision related to sales recorded in the period 885,322 30,073 16,220 61,271 Credits/payments issued during the period (987,202) (26,550) (15,598) (55,250) Balance at March 31, 2024 $ 457,454 $ 27,415 $ 137,108 $ 96,711

Alliance and Collaboration

Alliance and Collaboration	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Alliance and Collaboration	Alliance and Collaboration The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide R&D services over multiple periods. The Company’s significant arrangements are discussed below. Orion Corporation License Agreement On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of its complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance. During both the three months ended March 31, 2024 and 2023 , the Company recognized $0.6 million as a reduction to R&D expense related to services performed under the Orion Agreement. As of March 31, 2024, deferred income of $10.7 million and $1.2 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of December 31, 2023 , deferred income of $7.8 million and $4.7 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of March 31, 2024, no products have been supplied by Amneal under the Orion Agreement. Refer to Note 5. Alliance and Collaboration in our 2023 Annual Report on Form 10-K for additional information. ONGENTYS® License Agreement On December 5, 2023, the Company entered into a license agreement with BIAL-Portela & Ca., S.A. (“BIAL”) for the exclusive royalty-free right to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023 and ending at such time when generic opicapone sales reach certain predetermined thresholds (the “BIAL License Agreement”). ONGENTYS® is BIAL’s proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes. Under the BIAL Agreement, the Company is responsible for commercialization and marketing of ONGENTYS® in the U.S. and BIAL is responsible for manufacturing and supply. The BIAL Agreement also requires the Company to spend a minimum of $6.0 million in medical and marketing activities directly related to ONGENTYS®. The Company commenced distribution of ONGENTYS® during the three months ended March 31, 2024. During December 2023, the Company paid a nonrefundable license fee of $12.5 million to BIAL, which was capitalized as an intangible asset and will be amortized to cost of sales over a period of eight years. The BIAL License Agreement provides for potential future milestone payments totaling $22.5 million, depending on cumulative net sales of ONGENTYS®. Knight Therapeutics International S.A. License Agreement On January 24, 2024, the Company entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. (“Knight”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the “Knight License Agreement”). The Knight License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Knight will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight. On February 26, 2024, the Company received a nonrefundable license fee of $1.0 million from Knight, which was recorded as net revenue for the three months ended March 31, 2024. The Knight License Agreement provides for potential future milestone payments totaling $10.5 million, contingent upon regulatory approval, launch dates and cumulative net sales targets by Knight. The agreement also includes low-double digit royalty payments based on net sales of IPX203. License Agreement with Zambon Biotech On February 23, 2024, the Company entered into a license, distribution and supply agreement with Zambon Biotech S.A. (“Zambon”) granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the “Zambon License Agreement”). The term for the Zambon License Agreement is 15 years commencing from the commercial launch of the product, which can automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Zambon will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Zambon. In connection with the execution of the agreement, the Company was entitled to a non-refundable license fee of €5.0 million, or $5.4 million, which was received in April 2024. Of the license fee, the Company allocated €3.2 million, or $3.5 million, to the delivery of a functional license, which was recorded as net revenue during the three months ended March 31, 2024. In addition, the Company is eligible to receive future milestone payments totaling €71.5 million, or $77.2 million, from Zambon, contingent upon regulatory approval of the product, and achievement of certain annual net sales targets by Zambon. The Zambon License Agreement also includes single-digit to low-double digit royalty payments based on net sales of IPX203. Biosimilar Licensing and Supply Agreement Bevacizumab On May 7, 2018, the Company entered into a licensing and supply agreement with mAbxience S.L. (“mAbxience”), for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. Pursuant to the agreement, the Company will be the exclusive partner in the U.S. market and pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to mAbxience, up to $78.3 million. On April 13, 2022, the FDA approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of seven years. During the three months ended March 31, 2024, the Company paid a sales-based milestone of $9.5 million, which was capitalized as a product rights intangible asset and is being amortized to cost of sales. Denosumab On October 12, 2023, the Company entered into a licensing and supply agreement with mAbxience to be the exclusive U.S. partner for two denosumab biosimilars referencing both Prolia® and XGEVA®. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. mAbxience is responsible for the clinical and regulatory approval for the two products and regulatory fees will be shared by the parties. Upon approval of each product, mAbxience will be responsible for supply and the Company will be responsible for commercialization. During the year ended December 31, 2023, the Company recorded R&D expense for a $2.5 million payment made upon execution of the agreement and an additional $2.5 million for a developmental milestone. During the three months ended March 31, 2024, the Company recorded R&D expense for a $3.0 million payment made for a clinical milestone. The agreement provides for potential future milestone payments to mAbxience of up to $66.0 million as follows: (i) up to $3.5 million relating to clinical and developmental milestones; (ii) up to $15.0 million for regulatory approval and initial commercial launch milestones; and (iii) up to $47.5 million for the achievement of annual commercial milestones. Agreements with K ashiv Biosciences, LLC For details on the Company’s related party agreements with Kashiv Biosciences, LLC (“Kashiv”), refer to Note 19. Related Party Transactions in this Form 10-Q and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 31, 2024, the Company’s provision for income taxes and effective tax rate were $6.2 million and (8.2)%, respectively, as compared to $0.7 million and (7.1)%, respectively, for the three months ended March 31, 2023. For the three months ended March 31, 2024, the period-over-period change in the provision for income taxes was primarily related to changes in the jurisdictional mix of income. The Company recorded deferred tax assets for (i) its outside basis difference in its investment in Amneal on May 4, 2018, (ii) the net operating loss of Impax Laboratories, Inc., which was acquired by the Company in 2018, from January 1, 2018 through May 4, 2018, (iii) certain federal and state credits, and (iv) interest carryforwards of Impax that were attributable to the Company. The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others. The Company established a valuation allowance on its DTAs based upon all available objective and verifiable evidence, both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three-year pre-tax losses through March 31, 2024. As a result of the losses through March 31, 2024, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of March 31, 2024 and December 31, 2023, this valuation allowance was $566.0 million and $566.5 million, respectively, and reduced the carrying value of these gross DTAs to zero. In 2018, the Company entered into a tax receivable agreement (“TRA”) for which it was generally required to pay the holders of Amneal common units on a one-to-one basis, 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal common units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal common units for shares of Class A common stock of the Company prior to the Reorganization (as defined in Note 1. Nature of Operations in our 2023 Annual Report on Form 10-K) and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019. As part of the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the tax benefits subject to the TRA to 75% of such realized benefits. This agreement will not cause the acceleration of payments under the TRA. As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to the TRA; therefore, as of March 31, 2024 and December 31, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely-than-not in the future, at such time, these TRA liabilities (which amounted to approximately $185.0 million at March 31, 2024 and December 31, 2023) will be recorded through charges in the Company’s consolidated statements of operations. The timing and amount of any payments under the TRA may vary depending on the timing of the Company’s taxable income and the tax rate in effect at the time of realization of the Company’s taxable income. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that the Company may ultimately realize. Although the DTAs were not determined to be realizable as of March 31, 2024 and December 31, 2023, the Company assessed that a TRA liability of $5.7 million and $3.8 million at those dates, respectively, had become probable. For the three months ended March 31, 2024 and 2023, the Company recorded expenses associated with the TRA of $1.9 million and $0.8 million, respectively. In future periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, an estimate of payment will be accrued. Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA in excess of the $5.7 million accrued as of March 31, 2024 . Should the Company determine that a DTA with a valuation allowance is realizable in a subsequent period, the related valuation allowance will be reversed and, if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded. The Company continuously monitors government proposals to make changes to tax laws, including proposed legislation in certain foreign jurisdictions resulting from the adoption of the Organization for Economic Cooperation and Development (“OECD”) policies (refer to Note 7. Income Taxes in the Company’s 2023 Annual Report on Form 10-K). The OECD has issued a two-pillar approach to global taxation, focusing on global profit allocation and a global minimum tax rate of at least 15%. Legislation for the “Pillar Two” proposal, applying to the Company, has been enacted in Ireland, and it is effective with the financial year beginning on January 1, 2024. As the tax rates the other jurisdictions in which the Company operates exceed 15%, the Company does not believe there is any potential additional exposure besides in Ireland.

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Loss per Share	Loss per Share Following the implementation of the Reorganization on November 7, 2023, all outstanding shares of Old PubCo Class A common stock and Old PubCo Class B common stock were exchanged for an equivalent number of shares of Class A common stock of the Company. Basic loss per share of the Company’s Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share of Class A common stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding, adjusted to give effect to potentially dilutive securities. The weighted-average number of shares of Class A common stock for all periods prior to the Reorganization includes shares of Old PubCo Class A common stock. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts): Three Months Ended 2024 2023 Numerator: Net loss attributable to Amneal Pharmaceuticals, Inc. $ (91,643) $ (6,943) Denominator: Weighted-average shares outstanding - basic and diluted 307,279 152,109 Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Basic and diluted $ (0.30) $ (0.05) Prior to the Reorganization, shares of Old PubCo Class B common stock did not share in the losses of the Company and, therefore, were not participating securities. As such, separate presentation of basic and diluted loss per share of Old PubCo Class B common stock under the two-class method was not presented. Effective with the Reorganization, all outstanding shares of Old PubCo Class B common stock were surrendered and canceled. The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands): Three Months Ended 2024 2023 Stock options 2,406 (1) 2,632 (1) Restricted stock units 10,837 (1) 11,576 (1) Performance stock units 7,827 (1) 7,018 (1) Shares of Old PubCo Class B common stock — 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period. (2)

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Trade Accounts Receivable, Net	Trade Accounts Receivable, Net Trade accounts receivable, net was comprised of the following (in thousands): March 31, December 31, Gross accounts receivable $ 1,156,861 $ 1,199,980 Allowance for credit losses (3,037) (3,022) Contract charge-backs and sales volume allowances (457,454) (559,334) Cash discount allowances (27,415) (23,892) Subtotal (487,906) (586,248) Trade accounts receivable, net $ 668,955 $ 613,732 Concentration of Receivables Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: March 31, December 31, Customer A 32 % 40 % Customer B 29 % 24 % Customer C 23 % 22 %

Inventories

Inventories	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories were comprised of the following (in thousands): March 31, December 31, Raw materials $ 196,737 $ 217,744 Work in process 57,924 59,563 Finished goods 315,992 304,077 Total inventories $ 570,653 $ 581,384

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of the following (in thousands): March 31, December 31, Deposits and advances $ 1,935 $ 2,200 Prepaid insurance 4,780 8,334 Prepaid regulatory fees 4,219 6,331 Income and other tax receivables 12,198 13,168 Prepaid taxes 9,205 11,899 Other current receivables 12,802 9,929 Chargebacks receivable (1) 8,575 7,876 Other prepaid assets 33,584 22,948 Total prepaid expenses and other current assets $ 87,298 $ 82,685 (1) When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands): March 31, December 31, Balance, beginning of period $ 598,629 $ 598,853 Currency translation (80) (224) Balance, end of period $ 598,549 $ 598,629 As of March 31, 2024, $366.3 million, $162.7 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2023, $366.3 million, $162.8 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Weighted-Average Cost Accumulated Net Cost Accumulated Net Amortizing intangible assets: Product rights 6.2 $ 1,207,469 $ (739,351) $ 468,118 $ 1,198,971 $ (703,297) $ 495,674 Other intangible assets 3.1 111,800 (76,491) 35,309 111,800 (72,896) 38,904 Subtotal 1,319,269 (815,842) 503,427 1,310,771 (776,193) 534,578 In-process research and development 355,845 — 355,845 355,845 — 355,845 Total intangible assets $ 1,675,114 $ (815,842) $ 859,272 $ 1,666,616 $ (776,193) $ 890,423 Amortization expense related to intangible assets for the three months ended March 31, 2024 and 2023 was $39.9 million and $41.1 million, respectively. The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&D”) intangible assets (in thousands): Future Remainder of 2024 $ 119,432 2025 121,638 2026 73,115 2027 52,606 2028 33,263 2029 26,484 Thereafter 76,889 Total $ 503,427 The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. Intangible asset impairments were immaterial for the three months ended March 31, 2024 (none for the three months ended March 31, 2023). On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that, although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, the Company met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked the Company to perform a QT study, a routine cardiac safety study that is required for new drugs. On February 7, 2024, the Company provided a complete response resubmission to the FDA for IPX203. IPX203 has a Prescription Drug User Fee Act (PDUFA) decision date of August 7, 2024. No indicators of impairment of the Company’s IPX203 IPR&D intangible asset were identified during 2024. Additionally, there was no impairment recorded during 2023. While management believes the assumptions used in the Company’s 2023 annual impairment test of its IPX203 IPR&D intangible asset were reasonable and continue to be commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin, delaying the potential launch date, and lowering the probability of technical and regulatory success, could result in material future impairments of the Company’s IPX203 IPR&D intangible asset. Refer to Note 13. Goodwill and Other Intangible Assets in the Company’s Annual Report on Form 10-K for additional information.

Other Assets

Other Assets	3 Months Ended
	Mar. 31, 2024
Other Assets [Abstract]
Other Assets	Other Assets Other assets were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Interest rate swap (1) $ 52,632 $ 37,089 Security deposits 3,616 3,602 Long-term prepaid expenses 3,099 3,273 Deferred revolving credit facility costs 4,007 4,427 Other long term assets 10,393 7,126 Total $ 73,747 $ 55,517 (1) Refer to Note 15. Fair Value Measurements and Note 16. Financial Instruments

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Accounts payable $ 175,325 $ 143,572 Accrued returns allowance (1) 137,108 136,486 Accrued compensation 44,806 71,122 Accrued Medicaid and commercial rebates (1) 96,711 90,690 Accrued royalties 19,779 23,342 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 14,598 11,005 Accrued other 59,965 48,219 Total accounts payable and accrued expenses $ 558,518 $ 534,662 (1) Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2023 to March 31, 2024.

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	Debt There have been no material changes in the Company’s long-term debt since December 31, 2023, except as disclosed below. Refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for additional information and definitions of terms used in this note. The following is a summary of the Company’s indebtedness under its term loans (in thousands): March 31, 2024 December 31, 2023 Term Loan Due May 2025 $ 191,979 $ 191,979 Term Loan Due May 2028 2,336,949 2,351,647 Total debt 2,528,928 2,543,626 Less: debt issuance costs (117,561) (123,497) Total debt, net of debt issuance costs 2,411,367 2,420,129 Less: current portion of long-term debt (33,660) (34,125) Total long-term debt, net $ 2,377,707 $ 2,386,004 During the three months ended March 31, 2024, the Company (i) borrowed and repaid $20.0 million under the Amended New Revolving Credit Facility and (ii) borrowed and repaid $28.0 million under the Amended Rondo Revolving Credit Facility. As of each of March 31, 2024 and December 31, 2023, $179.0 million was outstanding on the Amended New Revolving Credit Facility.

Other Long-Term Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2024
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	Other Long-Term Liabilities Other long-term liabilities were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Uncertain tax positions $ 504 $ 497 Long-term compensation 18,073 21,283 Contingent consideration (1) 433 433 Other long-term liabilities 5,569 7,466 Total other long-term liabilities $ 24,579 $ 29,679 (1) Refer to Note 15. Fair Value Measurements for additional information.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands): Fair Value Measurement Based on March 31, 2024 Total Quoted Significant Significant Assets Interest rate swap (1) $ 52,632 $ — $ 52,632 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,668 $ — $ 9,668 $ — Contingent consideration liabilities (3) $ 1,021 $ — $ — $ 1,021 December 31, 2023 Assets Interest rate swap (1) $ 37,089 $ — $ 37,089 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,100 $ — $ 9,100 $ — Contingent consideration liability (3) $ 921 $ — $ — $ 921 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 16. Financial Instruments for information on the Company's interest rate swap. (2) These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3) The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. For the three months ended March 31, 2024, there was no material activity or payments related to the contingent consideration liabilities. There were no transfers between levels in the fair value hierarchy during the three months ended March 31, 2024. Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments. The following is a summary of the Company’s indebtedness at fair value (in thousands): March 31, 2024 December 31, 2023 Term Loan Due 2025 $ 192,099 $ 190,779 Term Loan Due 2028 $ 2,339,870 $ 2,328,130 Sellers Notes $ 41,944 $ 41,033 The Term Loan Due 2025 and Term Loan Due 2028 are in the Level 2 category within the fair value level hierarchy. The fair values were determined using market data for valuation. The Sellers Notes are in the Level 2 category within the fair value level hierarchy. Refer to Note 16 . Debt in the Company’s 2023 Annual Report on Form 10-K for detailed information about its indebtedness, including definitions of terms. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis There were no non-recurring fair value measurements during the three months ended March 31, 2024 and 2023.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates. Interest Rate Risk Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company’s debt obligations consist of variable-rate and fixed-rate debt instruments. The Company’s primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company initially entered into an interest rate swap on the Term Loan Due 2025. On November 14, 2023, in connection with the refinancing of the Term Loan Due 2025, the Company novated its swap agreement to another counterparty and, in connection with such novation, amended the interest rate swap agreement. Refer to the section “Interest Rate Derivative - Cash Flow Hedge” below and in Note 20. Financial Instruments in the Company’s 2023 Annual Report on Form 10-K for additional information and the definition of certain terms. Interest Rate Derivative – Cash Flow Hedge The inte rest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month London interbank offered rate (“LIBOR”) associated with the Term Loan Due 2025 (the “October 2019 Swap”). On May 31, 2023, the Company executed an amendment to the October 2019 Swap that, among other things, changed the variable reference rate from LIBOR to the one-month secured overnight financing rate (“SOFR”) (the “Amended October 2019 Swap”). On November 14, 2023, in connection with the Company’s refinancing of the Term Loan Due 2025 and the New Credit Facility (refer to Note 16. Debt in the Company’s 2023 Annual Report on Form 10-K for definitions and additional information), the Company novated the Amended October 2019 Swap to another counterparty and subsequently amended the interest rate agreement. Specifically, the amendments modified (i) the fixed rate payable by the counterparty from 1.3660% to a new fixed rate of 2.7877% and (ii) extended the termination date through May 4, 2027 (i.e., one year before the Term Loan Due 2028 matures) (the “November 2023 Swap”). The amendments did not change the notional amount of $1.3 billion. The purpose of the November 2023 Swap is to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month SOFR associated with the Term Loan Due 2028. The Company used a strategy commonly referred to as “blend and extend,” which allows the existing asset position of the swap agreement to be effectively blended into the new interest rate swap agreement. As a result of this transaction, on November 14, 2023, the Amended October 2019 Swap was de-designated and the unrealized gain of $66.7 million was recorded within accumulated other comprehensive (loss) income and will be amortized as a reduction of interest expense, net, over the original term of the of the Amended October 2019 Swap (until May 2025), as the hedged transactions affect earnings. Additionally, the November 2023 Swap had a fair value of $66.7 million at inception and will be ratably recorded to accumulated other comprehensive (loss) income and reclassified to interest expense, net, over the term of the November 2023 Swap, as the hedged transactions affect earnings. During the three months ended March 31, 2024, the Company reclassified a gain of $6.5 million from accumulated other comprehensive loss to interest expense, net. Approximately $26.1 million of net gains included in accumulated other comprehensive loss as of March 31, 2024 are expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Term Loan Due 2028 and amortization of the amounts included in accumulated other comprehensive loss occurs. As of March 31, 2024, the total gain, net of income taxes, related to the Company’s cash flow hedge of $42.8 million , was recognized in accumulated other comprehensive loss. A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): March 31, 2024 December 31, 2023 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 52,632 Other Assets $ 37,089

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Commercial Manufacturing, Collaboration, License, and Distribution Agreements The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 4. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 19. Related Party Transactions for additional information . Contingencies Legal Proceedings The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, how ever, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized. For the three months ended March 31, 2024, charges related to legal matters, net of $94.4 million were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. (refer to the section Civil Prescription Opioid Litigation below). For the three months ended March 31, 2023, credit related to legal matters, net of $0.4 million was comprised of a litigation settlement gain, partially offset by charges for legal proceedings. Liabilities for legal matters were comprised of the following (in thousands): Matter March 31, 2024 December 31, 2023 Opana ER® antitrust litigation $ — $ 50,000 Opana ER® antitrust litigation-accrued interest — 2,347 Civil prescription opioid litigation 30,130 21,189 Other — 3,452 Current portion of liabilities for legal matters $ 30,130 $ 76,988 Civil prescription opioid litigation (Liabilities for legal matters - long term) $ 85,479 $ 316 Refer to the respective discussions below for additional information about the significant matters in the tables above. Refer to Note 21. Commitments and Contingencies in our Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters and Patent Litigation. Other Litigation Related to the Company’s Business Opana ER® Antitrust Litigation From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) of Opana ER® were filed against Endo Pharmaceuticals Inc. and Impax Laboratories, Inc. (“Impax”) and consolidated into multi-district litigation (“MDL”) in the U.S. District Court for the Northern District of Illinois. Impax subsequently entered into settlement agreements with all of the plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the plaintiffs’ claims. As of December 31, 2023, the liability for the final settlement payment of $50.0 million, plus 3% stated interest thereon, was included in the current portion of liabilities for legal matters and was paid in January 2024 with cash on hand. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved. United States Department of Justice Investigations On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation. On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. The Company is cooperating with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. In Re Generic Pharmaceuticals Pricing Antitrust Litigation Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania ( In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa . )) (“MDL No. 2724”). On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original plaintiff states. Both the May 10, 2019 and June 10, 2020 lawsuits seek unspecified monetary damages and penalties and equitable relief including disgorgement and restitution, and both were incorporated into MDL No. 2724. The June 10, 2020 lawsuit was selected for bellwether status. The States of Alabama, Hawaii and Arkansas, and the Territory of Guam voluntarily dismissed all of their claims in the two actions against all defendants, including the Company. American Samoa voluntarily dismissed its claims in the May 10, 2019 action and was not named as a plaintiff in the June 10, 2020 action. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. On November 1, 2023, the Attorneys General filed a Motion to Remand their cases to the State of Connecticut. On January 21, 2024, the Joint Panel on Multidistrict Litigation (“JPML”) granted the motion, and these cases were formally remanded in April 2024. See Connecticut, et al. v. Teva Pharmaceuticals USA, Inc., et al., 3:19-cv-00710-MPS and Connecticut, et al. v. Sandoz, Inc. et al., 3:20-cv-00803-MPS . Fact discovery in MDL No. 2724 is proceeding as to both bellwether and non-bellwether cases, and expert discovery as to bellwether cases is also underway. No trial date has been set. No schedule has yet been issued in the May 10, 2019 and June 10, 2020 actions brought by the State Attorneys General, which have now been remanded to the District of Connecticut. On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present ( Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The certification hearing date is scheduled for December 2024, but subject to court approval, the hearing date may be rescheduled on consent to May 2025. The Company is preparing a response to the motion to certify in advance of that date. Civil Prescription Opioid Litigation The Company and certain of its affiliates are named as defendants in over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act, state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there have been numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804) (the “Opioid MDL”). The Company is also named in various state court cases pending in seven states. No firm trial dates have been set except in Texas (January 31, 2025, trial-ready date (Dallas County)). The Company reached a settlement agreement with the New Mexico Attorney General to resolve its claims against the Company, which was finalized on April 24, 2023. A Consent Judgment dismissing the case was entered on May 15, 2023. The Company reached a settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions, which was signed on May 25, 2023. The two neonatal abstinence syndrome cases in West Virginia state court were dismissed on May 31, 2023 and were subsequently appealed by the plaintiffs. These appeals remain pending. The hospital cases pending in West Virginia state court were dismissed on May 2, 2023. The Company reached a preliminary settlement with a group of private hospitals in Alabama in June 2023 to resolve the hospitals’ claims against the Company. The Company anticipates a final determination approving the settlement by the end of the second quarter of 2024. On February 7, 2024, the Company was dismissed from the Mobile County Board of Health case. The Company previously reported an August 12, 2024 trial date for that case. On January 13, 2023, the Company re ceived a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. On January 4, 2024, the Company received a CID issued by the Alaska Attorney General seeking information regarding its business concerning opioid-containing products. The Company is evaluating the CID. In late April 2024, the Company reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American tribes across the U.S. The settlement in principle is subject to the negotiation and execution of a definitive settlement agreement between the parties. The settlement would be payable over ten years. Under the settlement in principle, the Company would agree to pay $92.5 million in cash and provide $180.0 million (valued at $125/ twin pack) in naloxone nasal spray to help treat opioid overdoses. In lieu of receiving product, the settling parties can opt to receive 25% of the naloxone nasal spray’s value (up to $45.0 million) in cash during the last four years of the ten years payment term, which could increase the total amount of cash the Company would agree to pay up to $137.5 million. As of March 31, 2024, the Company concluded the loss related to the opioid litigation was probable, and the related loss was reasonably estimable considering the settlement in principle. As a result, the Company recorded a charge of $94.4 million associated with the settlement in principle during the three months ended March 31, 2024 to increase the liability as of March 31, 2024, to $115.6 million, of which $85.5 million was classified as long-term. While this liability has been deemed reasonable by the Company’s management, it could significantly change as the definitive settlement agreement is finalized. As of December 31, 2023, the Company had a liability of $21.5 million related to its prescription opioid litigation, of which $0.3 million was classified as long-term. For the remaining cases not covered by the settlement in principle, primarily brought by other hospitals, schools and individuals, the Company has not recorded a liability as of March 31, 2024 or December 31, 2023, because it concluded that a loss was not probable and estimable. United States Department of Justice / Drug Enforcement Administration Subpoenas On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements with the USAO through May 15, 2024. It is not possible to determine the exact outcome of these investigations. On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney for the Southern District of Florida (the “AUSA”). The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation. On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation. Ranitidine Litigation The Company and its affiliates were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company, without leave to file further amended complaints, holding all claims were preempted. Plaintiffs appealed the MDL Court’s dismissals to the 11th Circuit Court of Appeals. On November 7, 2022, the 11th Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The 11th Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed their merits brief on April 10, 2024. The Company and its affiliates have also been named as defendants in various state lawsuits in five states in which the Company has filed motions to dismiss or plans to file motions to dismiss in the future. On August 17, 2023, the judge in the consolidated Illinois state court cases granted a motion to dismiss all such cases in which the Company and affiliates had been named, holding all claims preempted. There are no trial dates involving the Company in any of the state court cases. Metformin Litigation Amneal and AvKARE, LLC (improperly named as AvKARE, Inc.) were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey, consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH) (“ In re Metformin ”). The lawsuits allege economic loss in connection with their purchase or reimbursements due to the alleged contamination of generic metformin products with NDMA. Plaintiffs have voluntarily dismissed their claims seeking medical monitoring or evaluation due to their consummation of allegedly contaminated metformin. The parties are currently engaged in discovery. On October 17, 2023, co-defendant Rite-Aid filed a suggestion of bankruptcy and automatic stay of proceeding. AvKARE, LLC has been dismissed from this action. Three additional similar putative class action lawsuits filed against Amneal and AvKARE, LLC have been consolidated for discovery and pretrial purposes only, Marcia E. Brice v. Amneal Pharmaceuticals, Inc., No. 2:20-cv-13728 (D.N.J.), Michael Hann v. Amneal Pharmaceuticals of New York, LLC et al., No. 2:23-cv-22902 (D.N.J.), and In re Metformin: County of Monmouth, et al. v. Apotex Inc., et al. , No. 2:23-cv-21001-MAC-MAH (D.N.J.) (“County of Monmouth”). Pursuant to a Stipulation and Order entered on the docket on May 2, 2024, plaintiffs will file a third amended complaint in In re Metformin which includes the claims and parties in County of Monmouth. The third amended complaint must be filed within three days of entry of the Stipulation and Order. Immediately preceding the filing of the third amended complaint, the County of Monmouth First Amended Complaint will be voluntarily dismissed without prejudice. Defendants may file a motion to dismiss the third amended complaint within thirty days of the filing of the third amended complaint. On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin ( Davis v. Camber Pharmaceuticals, Inc. , et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation multi-district litigation for pretrial proceedings. Xyrem® (Sodium Oxybate) Antitrust Litigation Amneal was named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. The actions were consolidated in the United States District Court for the Northern District of California for pretrial proceedings ( In re Xyrem (Sodium Oxybate) Antitrust Litigation , No. 5:20-md-02966-LHK (N.D. Cal.)). Amneal was also named as a defendant in a similar action filed by Aetna Inc. (“Aetna”) in California state court (Aetna Inc. v. Jazz Pharms., Inc. et. al , No. 22CV010951 (Cal. Super. Ct.). The California state court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On August 25, 2023, Aetna filed a motion seeking leave to file a second amended complaint adding Amneal as a defendant, which the Court tentatively granted on October 20, 2023. Aetna filed a second amended complaint naming Amneal on November 17, 2023. On February 28, 2023, Amneal executed a $1.9 million settlement agreement with class plaintiffs in the federal litigation. Class plaintiffs filed a motion for final approval of the settlement on November 10, 2023, and entered an order granting final approval, certifying settlement class, and dismissing class plaintiffs’ against Amneal with prejudice on April 17, 2024. On December 18, 2023, Amneal executed a $4.0 million settlement with Aetna, United Healthcare Services, Inc. (“United”), Humana Inc. (“Humana”), Molina Healthcare Inc. (“Molina”), and Health Care Service Corporation (“HCSC”). Pursuant to that settlement, the federal court dismissed United, Humana, Molina and HCSC’s claims against Amneal, with prejudice, on February 26, 2024, and the California state court dismissed Aetna’s claims against Amneal, with prejudice, on February 29, 2024. Thus, all claims against Amneal in the federal and state court have been voluntarily dismissed with prejudice pursuant to settlements. In December 2023, the Company recorded $3.0 million for the settlement of claims associated with Xyrem® antitrust litigation. As of December 31, 2023, the Company had a liability of $2.0 million associated with this settlement, which was paid in January 2024. UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal ( UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma. U.S.A., Inc. et al, No. 1:23-cv-10030 (S.D.N.Y.). The plaintiff health plans seek to represent a class of third party payers and alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® to maintain higher prices, in violation of the antitrust laws. On February 28, 2024, Takeda filed a motion to transfer the case to the United States District Court for the Eastern District of Pennsylvania. On March 13, 2024 and March 27, 2024, Amneal submitted a letter and brief, respectively, informing the Court of its position that the Eastern District of Pennsylvania lacks personal jurisdiction over Amneal. The deadline for defendants to respond to the complaint is 45 days after the date on which the motion to transfer is resolved. Indian Tax Authority Matters

Stockholders_ Equity and Redeem

Stockholders’ Equity and Redeemable Non-Controlling Interests	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Equity and Redeemable Non-Controlling Interests	Stockholders’ Equity and Redeemable Non-Controlling Interests Effective with the Reorganization on November 7, 2023, the Company holds 100% of the Amneal Common Units. In connection with the Reorganization, the Company amended and restated its certificate of incorporation. The voting rights, dividend rights and participation rights of holders of Class A common stock of the Company did not materially change as a result of the amendment. There were no shares of Class B common stock of the Company outstanding as of December 31, 2023. Non-Controlling Interests The consolidated financial statements of the Company include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Prior to the Reorganization, non-controlling interests were adjusted for capital transactions that impact the non-publicly held economic interests in Amneal. Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the three months ended March 31, 2023, the Company recorded net tax distributions to the Members of $26.8 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members. The Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP , a related party, hold the remaining interests. The Company attributes 2% of the net income or loss of KSP to non-controlling interests. Redeemable Non-Controlling Interests The Company acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”), in 2020. The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Because the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests. The Company attributes 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For the three months ended March 31, 2024 and 2023, the Company recorded tax distributions of $4.4 million and $3.0 million, respectively, as a reduction of redeemable non-controlling interests, respectively. Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands): Foreign Unrealized gain (loss) on cash flow hedge, net of tax Accumulated other comprehensive (loss) income Balance December 31, 2023 $ (66,072) $ 33,723 $ (32,349) Other comprehensive loss before reclassification (390) 15,543 15,153 Reclassification of cash flow hedge to earnings, net of tax of $0 — (6,515) (6,515) Balance March 31, 2024 $ (66,462) $ 42,751 $ (23,711) Balance December 31, 2022 $ (32,382) $ 42,321 $ 9,939 Other comprehensive loss before reclassification 898 (7,135) (6,237) Reallocation of ownership interests (195) 257 62 Balance March 31, 2023 $ (31,679) $ 35,443 $ 3,764

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company has various business agreements with certain parties in which there is some common ownership. However, the Company does not directly own or manage any of such related parties. Except as disclosed below, as of and for the three months ended March 31, 2024, there were no material changes to our related party agreements or relationships as described in Note 24. Related Party Transactions and Note 22. Stockholders’ Equity in our 2023 Annual Report on Form 10-K. The following table summarizes the Company’s related party transactions (in thousands): Three Months Ended March 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2024 2023 Kashiv Biosciences LLC Parking space lease Research and development $ 25 $ 17 Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development $ — $ 50 Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra) Cost of goods sold $ 4,526 $ 144 Storage agreement Research and development $ (77) $ (48) Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra) Inventory and cost of goods sold $ 1,216 $ — Generic development supply agreement - research and development material Research and development $ (48) $ — Generic development supply agreement - development activity deferred income Deferred revenue and net revenue $ (422) $ — Development and commercialization agreement - Long-acting injectable Research and development $ 500 $ — Other Related Parties Kanan, LLC - operating lease Inventory and cost of goods sold $ 592 $ 566 Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 314 $ 305 Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 5,001 $ 1,836 Tracy Properties LLC - operating lease Selling, general and administrative $ 143 $ 169 AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 2,312 $ 575 AvPROP, LLC - operating lease Selling, general and administrative $ 44 $ 47 Avtar Investments, LLC - consulting services Research and development $ 69 $ 188 Alkermes Inventory and cost of goods sold $ 12 $ 2 R&S Solutions - logistics services Selling, general and administrative $ — $ 20 Members - tax receivable agreement (TRA liability) Other expense $ 1,948 $ 826 The following table summarizes the amounts due to or from the Company for related party transa ctions (in thousands): March 31, 2024 December 31, 2023 Kashiv - various agreements $ 1,434 $ 954 Apace Packaging, LLC - packaging agreement 9 — Alkermes — 1 AzaTech Pharma LLC 78 — Related party receivables - short term $ 1,521 $ 955 Kashiv - various agreements $ 5,773 $ 3,179 Apace Packaging, LLC - packaging agreement 1,863 1,091 AzaTech Pharma LLC - supply agreement 1,650 1,958 Avtar Investments LLC - consulting services 22 100 Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 Members - tax receivable agreement 3,532 549 Rondo Class B unit holders - tax distributions 3,777 — Alkermes Plc 16 2 Related party payables - short term $ 17,075 $ 7,321 Kashiv - contingent consideration $ 530 $ 430 Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 8,691 8,139 Members - tax receivable agreement 2,173 3,207 Related party payables - long term $ 11,394 $ 11,776 Kashiv Biosciences Amendment to Biosimilar License Agreement In March 2024, the Company amended the Kashiv Biosimilar Agreement (as defined in Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K) to include two additional in-development products, a pre-filled auto-injector delivery system for peg-filgrastim and a pre-filled on-body injector (OBI) delivery system for peg-filgrastim. Consistent with the existing terms, Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities of these product candidates. The amendment did not change the contractual terms related to existing commercialized biosimilar products. The amendment provides an incremental $14.5 million in potential future milestone payments specific to these in-development products, including $7.0 million for clinical and developmental milestones and $7.5 million for regulatory approval and first commercial-sales milestones. In addition, the amendment clarifies that future net sales milestones payments of up to $37.5 million, which did not change, shall be contingent upon reaching certain commercial sales volume objectives for the aggregate of all products under the amended agreement. The agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. No amounts were paid or recognized during the three months ended March 31, 2024 pursuant to this amendment . Long-Acting Injectable License and Supply Agreement In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal is responsible for manufacturing batch products and performing certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, is responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services. Pursuant to the development supply agreement, Amneal maintained a right of first offer and negotiation to the licensing of each generic product candidate. In March 2024, Amneal and Kashiv entered into a license and supply agreement for the development and commercialization of a long-acting injectable (the “Injectable License and Supply Agreement"). The existing development supply agreement remains effective for the remaining three generic product candidates. Subject to the terms of the Injectable License and Supply Agreement, Amneal is responsible for development, regulatory approval, and commercialization of the product candidate in the U.S., whereas Kashiv is responsible for development and regulatory approval of the product candidate for all other territories outside the U.S. Contingent upon Kashiv obtaining regulatory approval outside the U.S., Amneal shall manufacture the commercial supply for Kashiv at a stated price. The term of the agreement is 10 years from the respective product’s launch date in the U.S. During the three months ended March 31, 2024, the Company recorded R&D expense for a $0.5 million payment made upon execution of the license and supply agreement. The agreement provides for potential future milestone payments to Kashiv of up to $35.0 million as follows: (i) up to $10.0 million relating to developmental milestones; (ii) up to $20.0 million for U.S. regulatory approval and initial commercial launch milestones; and (iii) up to $5.0 million for the achievement of annual commercial milestones. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. Refer to Note 3. Acquisitions and Note 24. Related Party Transactions in the Company’s 2023 Annual Report on Form 10-K for information on the Company’s agreements with Kashiv.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has three reportable segments: Generics, Specialty, and AvKARE. Generics The Company’s Generics segment includes a retail and institutional portfolio of over 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Specialty The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders. AvKARE The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. Chief Operating Decision Makers The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, because they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment because it is not reviewed by the Company’s chief operating decision makers. The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands): Three Months Ended March 31, 2024 Generics (1) Specialty AvKARE (1) Corporate and Other Total Company Net revenue $ 391,294 $ 105,234 $ 162,663 $ — $ 659,191 Cost of goods sold 239,922 44,800 136,409 — 421,131 Gross profit 151,372 60,434 26,254 — 238,060 Selling, general and administrative 33,085 25,196 14,907 39,407 112,595 Research and development 34,371 4,927 — — 39,298 Intellectual property legal development expenses 960 24 — — 984 Restructuring and other charges — 946 — 524 1,470 Change in fair value of contingent consideration — 100 — — 100 Charges related to legal matters, net 94,359 — — — 94,359 Operating (loss) income $ (11,403) $ 29,241 $ 11,347 $ (39,931) $ (10,746) Three Months Ended March 31, 2023 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue $ 343,806 $ 91,678 $ 122,056 $ — $ 557,540 Cost of goods sold 230,551 43,191 105,612 — 379,354 Gross profit 113,255 48,487 16,444 — 178,186 Selling, general and administrative 27,600 22,379 12,940 39,177 102,096 Research and development 32,359 6,331 — — 38,690 Intellectual property legal development expenses 1,624 20 — — 1,644 Restructuring and other charges 99 — — 411 510 Change in fair value of contingent consideration — 2,457 — — 2,457 (Credit) charges related to legal matters, net (2,444) — — 2,008 (436) Other operating income (1,224) — — — (1,224) Operating income (loss) $ 55,241 $ 17,300 $ 3,504 $ (41,596) $ 34,449 (1) Operating results for the sale of Amneal products by AvKARE are included in Generics.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventOn April 30, 2024, Amneal closed on the sale of a wholly owned subsidiary in India to Kashiv for total consideration of ₹1 billion, or approximately $12 million. Total consideration consisted of a ₹416 million, or approximately $5 million, cash payment at closing and the assumption of a loan payable of approximately ₹600 million, or approximately $7 million, payable to another subsidiary of Amneal in India. The loan payable bears interest of 11% on the unpaid principal and is due on or before December 31, 2024. The Company is permitted to offset royalties or other amounts payable to Kashiv with any overdue principal on the loan payable. The subsidiary’s assets and liabilities were primarily comprised of a building under construction and a note payable, respectively. The subsidiary had no business activity, other than the construction of the building.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023 and the results of its operations, its comprehensive loss and its changes in stockholders’ equity (deficiency) for the three months ended March 31, 2024 and 2023. The consolidated balance sheet data at December 31, 2023 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP. Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2023 Annual Report on Form 10-K.
Use of Estimates	Use of Estimates The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Reclassifications	Reclassification The prior period balance related to the TRA (as defined in Note 5. Income Taxes ) of $0.8 million, formerly included in other income, net for the three months ended March 31, 2023, has been reclassified to the income statement caption “increase in tax receivable agreement liability” to conform to the current period presentation in the consolidated statements of operations. This reclassification did not impact total other expense, net or net loss.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Performance Obligations	The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue: Three Months Ended March 31, 2024 2023 Customer A 21 % 22 % Customer B 15 % 14 % Customer C 23 % 20 % Customer D 10 % 9 %
Schedule of Disaggregated Revenue	The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands): Three Months Ended March 31, 2024 2023 Generics Anti-infective $ 6,110 $ 5,174 Hormonal / allergy 107,714 104,851 Antiviral 3,866 25,474 Central nervous system 109,456 84,582 Cardiovascular system 45,878 32,503 Gastroenterology 18,197 14,364 Oncology 38,533 10,578 Metabolic disease / endocrine 11,185 9,265 Respiratory 11,136 12,815 Dermatology 18,975 18,004 Other therapeutic classes 18,523 25,895 International and other 1,721 301 Total Generics net revenue 391,294 343,806 Specialty Hormonal / allergy 29,375 24,763 Central nervous system 66,276 60,139 License agreement (1) 4,479 — Other therapeutic classes 5,104 6,776 Total Specialty net revenue 105,234 91,678 AvKARE Distribution 109,713 83,230 Government label 34,952 24,516 Institutional 10,858 8,862 Other 7,140 5,448 Total AvKARE net revenue 162,663 122,056 Total net revenue $ 659,191 $ 557,540 (1) Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement.
Schedule of Major Categories of Sales-Related Deductions	A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands): Contract Cash Discount Accrued Accrued Balance at December 31, 2023 $ 559,334 $ 23,892 $ 136,486 $ 90,690 Provision related to sales recorded in the period 885,322 30,073 16,220 61,271 Credits/payments issued during the period (987,202) (26,550) (15,598) (55,250) Balance at March 31, 2024 $ 457,454 $ 27,415 $ 137,108 $ 96,711

Loss per Share (Tables)

Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Loss per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted loss per share of Class A common stock (in thousands, except per share amounts): Three Months Ended 2024 2023 Numerator: Net loss attributable to Amneal Pharmaceuticals, Inc. $ (91,643) $ (6,943) Denominator: Weighted-average shares outstanding - basic and diluted 307,279 152,109 Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Basic and diluted $ (0.30) $ (0.05)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share	The following table presents potentially dilutive securities excluded from the computations of diluted loss per share of Class A common stock (in thousands): Three Months Ended 2024 2023 Stock options 2,406 (1) 2,632 (1) Restricted stock units 10,837 (1) 11,576 (1) Performance stock units 7,827 (1) 7,018 (1) Shares of Old PubCo Class B common stock — 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period. (2)

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Schedule of Trade Accounts Receivable, Net	Trade accounts receivable, net was comprised of the following (in thousands): March 31, December 31, Gross accounts receivable $ 1,156,861 $ 1,199,980 Allowance for credit losses (3,037) (3,022) Contract charge-backs and sales volume allowances (457,454) (559,334) Cash discount allowances (27,415) (23,892) Subtotal (487,906) (586,248) Trade accounts receivable, net $ 668,955 $ 613,732
Schedules of Percent of Gross Trade Receivables	Concentration of Receivables Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: March 31, December 31, Customer A 32 % 40 % Customer B 29 % 24 % Customer C 23 % 22 %

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Components of Inventories	Inventories were comprised of the following (in thousands): March 31, December 31, Raw materials $ 196,737 $ 217,744 Work in process 57,924 59,563 Finished goods 315,992 304,077 Total inventories $ 570,653 $ 581,384

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets were comprised of the following (in thousands): March 31, December 31, Deposits and advances $ 1,935 $ 2,200 Prepaid insurance 4,780 8,334 Prepaid regulatory fees 4,219 6,331 Income and other tax receivables 12,198 13,168 Prepaid taxes 9,205 11,899 Other current receivables 12,802 9,929 Chargebacks receivable (1) 8,575 7,876 Other prepaid assets 33,584 22,948 Total prepaid expenses and other current assets $ 87,298 $ 82,685 (1) When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback receivable and a reduction to cost of goods sold in the same period as the related sale.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in goodwill for the three months ended March 31, 2024 and for the year ended December 31, 2023 were as follows (in thousands): March 31, December 31, Balance, beginning of period $ 598,629 $ 598,853 Currency translation (80) (224) Balance, end of period $ 598,549 $ 598,629
Schedule of Finite-Lived Intangible Assets	Intangible assets as of March 31, 2024 and December 31, 2023 were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Weighted-Average Cost Accumulated Net Cost Accumulated Net Amortizing intangible assets: Product rights 6.2 $ 1,207,469 $ (739,351) $ 468,118 $ 1,198,971 $ (703,297) $ 495,674 Other intangible assets 3.1 111,800 (76,491) 35,309 111,800 (72,896) 38,904 Subtotal 1,319,269 (815,842) 503,427 1,310,771 (776,193) 534,578 In-process research and development 355,845 — 355,845 355,845 — 355,845 Total intangible assets $ 1,675,114 $ (815,842) $ 859,272 $ 1,666,616 $ (776,193) $ 890,423
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of in-process research and development (“IPR&D”) intangible assets (in thousands): Future Remainder of 2024 $ 119,432 2025 121,638 2026 73,115 2027 52,606 2028 33,263 2029 26,484 Thereafter 76,889 Total $ 503,427

Other Assets (Tables)

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Other Assets [Abstract]
Schedule of Other Assets	Other assets were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Interest rate swap (1) $ 52,632 $ 37,089 Security deposits 3,616 3,602 Long-term prepaid expenses 3,099 3,273 Deferred revolving credit facility costs 4,007 4,427 Other long term assets 10,393 7,126 Total $ 73,747 $ 55,517 (1) Refer to Note 15. Fair Value Measurements and Note 16. Financial Instruments

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Accounts payable $ 175,325 $ 143,572 Accrued returns allowance (1) 137,108 136,486 Accrued compensation 44,806 71,122 Accrued Medicaid and commercial rebates (1) 96,711 90,690 Accrued royalties 19,779 23,342 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 14,598 11,005 Accrued other 59,965 48,219 Total accounts payable and accrued expenses $ 558,518 $ 534,662 (1) Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2023 to March 31, 2024.

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following is a summary of the Company’s indebtedness under its term loans (in thousands): March 31, 2024 December 31, 2023 Term Loan Due May 2025 $ 191,979 $ 191,979 Term Loan Due May 2028 2,336,949 2,351,647 Total debt 2,528,928 2,543,626 Less: debt issuance costs (117,561) (123,497) Total debt, net of debt issuance costs 2,411,367 2,420,129 Less: current portion of long-term debt (33,660) (34,125) Total long-term debt, net $ 2,377,707 $ 2,386,004

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-Term Liabilities	Other long-term liabilities were comprised of the following (in thousands): March 31, 2024 December 31, 2023 Uncertain tax positions $ 504 $ 497 Long-term compensation 18,073 21,283 Contingent consideration (1) 433 433 Other long-term liabilities 5,569 7,466 Total other long-term liabilities $ 24,579 $ 29,679 (1) Refer to Note 15. Fair Value Measurements for additional information.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands): Fair Value Measurement Based on March 31, 2024 Total Quoted Significant Significant Assets Interest rate swap (1) $ 52,632 $ — $ 52,632 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,668 $ — $ 9,668 $ — Contingent consideration liabilities (3) $ 1,021 $ — $ — $ 1,021 December 31, 2023 Assets Interest rate swap (1) $ 37,089 $ — $ 37,089 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,100 $ — $ 9,100 $ — Contingent consideration liability (3) $ 921 $ — $ — $ 921 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 16. Financial Instruments for information on the Company's interest rate swap. (2) These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3)
Summary of the Company’s Indebtedness at Fair Value	The following is a summary of the Company’s indebtedness at fair value (in thousands): March 31, 2024 December 31, 2023 Term Loan Due 2025 $ 192,099 $ 190,779 Term Loan Due 2028 $ 2,339,870 $ 2,328,130 Sellers Notes $ 41,944 $ 41,033

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets	A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): March 31, 2024 December 31, 2023 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 52,632 Other Assets $ 37,089

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Charges and Liabilities Related to Legal Matters	Liabilities for legal matters were comprised of the following (in thousands): Matter March 31, 2024 December 31, 2023 Opana ER® antitrust litigation $ — $ 50,000 Opana ER® antitrust litigation-accrued interest — 2,347 Civil prescription opioid litigation 30,130 21,189 Other — 3,452 Current portion of liabilities for legal matters $ 30,130 $ 76,988 Civil prescription opioid litigation (Liabilities for legal matters - long term) $ 85,479 $ 316

Stockholders_ Equity and Rede_2

Stockholders’ Equity and Redeemable Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive (Loss) Income by Component	Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands): Foreign Unrealized gain (loss) on cash flow hedge, net of tax Accumulated other comprehensive (loss) income Balance December 31, 2023 $ (66,072) $ 33,723 $ (32,349) Other comprehensive loss before reclassification (390) 15,543 15,153 Reclassification of cash flow hedge to earnings, net of tax of $0 — (6,515) (6,515) Balance March 31, 2024 $ (66,462) $ 42,751 $ (23,711) Balance December 31, 2022 $ (32,382) $ 42,321 $ 9,939 Other comprehensive loss before reclassification 898 (7,135) (6,237) Reallocation of ownership interests (195) 257 62 Balance March 31, 2023 $ (31,679) $ 35,443 $ 3,764

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The following table summarizes the Company’s related party transactions (in thousands): Three Months Ended March 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2024 2023 Kashiv Biosciences LLC Parking space lease Research and development $ 25 $ 17 Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development $ — $ 50 Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra) Cost of goods sold $ 4,526 $ 144 Storage agreement Research and development $ (77) $ (48) Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra) Inventory and cost of goods sold $ 1,216 $ — Generic development supply agreement - research and development material Research and development $ (48) $ — Generic development supply agreement - development activity deferred income Deferred revenue and net revenue $ (422) $ — Development and commercialization agreement - Long-acting injectable Research and development $ 500 $ — Other Related Parties Kanan, LLC - operating lease Inventory and cost of goods sold $ 592 $ 566 Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 314 $ 305 Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 5,001 $ 1,836 Tracy Properties LLC - operating lease Selling, general and administrative $ 143 $ 169 AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 2,312 $ 575 AvPROP, LLC - operating lease Selling, general and administrative $ 44 $ 47 Avtar Investments, LLC - consulting services Research and development $ 69 $ 188 Alkermes Inventory and cost of goods sold $ 12 $ 2 R&S Solutions - logistics services Selling, general and administrative $ — $ 20 Members - tax receivable agreement (TRA liability) Other expense $ 1,948 $ 826 The following table summarizes the amounts due to or from the Company for related party transa ctions (in thousands): March 31, 2024 December 31, 2023 Kashiv - various agreements $ 1,434 $ 954 Apace Packaging, LLC - packaging agreement 9 — Alkermes — 1 AzaTech Pharma LLC 78 — Related party receivables - short term $ 1,521 $ 955 Kashiv - various agreements $ 5,773 $ 3,179 Apace Packaging, LLC - packaging agreement 1,863 1,091 AzaTech Pharma LLC - supply agreement 1,650 1,958 Avtar Investments LLC - consulting services 22 100 Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 Members - tax receivable agreement 3,532 549 Rondo Class B unit holders - tax distributions 3,777 — Alkermes Plc 16 2 Related party payables - short term $ 17,075 $ 7,321 Kashiv - contingent consideration $ 530 $ 430 Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 8,691 8,139 Members - tax receivable agreement 2,173 3,207 Related party payables - long term $ 11,394 $ 11,776

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Three Months Ended March 31, 2024 Generics (1) Specialty AvKARE (1) Corporate and Other Total Company Net revenue $ 391,294 $ 105,234 $ 162,663 $ — $ 659,191 Cost of goods sold 239,922 44,800 136,409 — 421,131 Gross profit 151,372 60,434 26,254 — 238,060 Selling, general and administrative 33,085 25,196 14,907 39,407 112,595 Research and development 34,371 4,927 — — 39,298 Intellectual property legal development expenses 960 24 — — 984 Restructuring and other charges — 946 — 524 1,470 Change in fair value of contingent consideration — 100 — — 100 Charges related to legal matters, net 94,359 — — — 94,359 Operating (loss) income $ (11,403) $ 29,241 $ 11,347 $ (39,931) $ (10,746) Three Months Ended March 31, 2023 Generics (1) Specialty AvKARE (1) Corporate Total Net revenue $ 343,806 $ 91,678 $ 122,056 $ — $ 557,540 Cost of goods sold 230,551 43,191 105,612 — 379,354 Gross profit 113,255 48,487 16,444 — 178,186 Selling, general and administrative 27,600 22,379 12,940 39,177 102,096 Research and development 32,359 6,331 — — 38,690 Intellectual property legal development expenses 1,624 20 — — 1,644 Restructuring and other charges 99 — — 411 510 Change in fair value of contingent consideration — 2,457 — — 2,457 (Credit) charges related to legal matters, net (2,444) — — 2,008 (436) Other operating income (1,224) — — — (1,224) Operating income (loss) $ 55,241 $ 17,300 $ 3,504 $ (41,596) $ 34,449 (1) Operating results for the sale of Amneal products by AvKARE are included in Generics.

Nature of Operations - Addition

Nature of Operations - Additional Information (Details)	Mar. 31, 2024	Nov. 07, 2023
Amneal Pharmaceuticals, LLC
Noncontrolling Interest [Line Items]
Ownership by parent (percent)	100%	100%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accounting Policies [Abstract]
Increase in tax receivable agreement liability	$ (1,948)	$ (826)
Liabilities for legal matters - long term	$ 85,479		$ 316

Revenue Recognition - Concentra

Revenue Recognition - Concentration of Revenue (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	21%	22%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	15%	14%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	23%	20%
Customer D
Concentration Risk [Line Items]
Concentration risk (percent)	10%	9%

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Net revenue	$ 659,191	$ 557,540
Generics
Disaggregation of Revenue [Line Items]
Net revenue	391,294	343,806
Specialty
Disaggregation of Revenue [Line Items]
Net revenue	105,234	91,678
AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	162,663	122,056
International and other | Generics
Disaggregation of Revenue [Line Items]
Net revenue	1,721	301
Anti-infective | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	6,110	5,174
Hormonal / allergy | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	107,714	104,851
Hormonal / allergy | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	29,375	24,763
Antiviral | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	3,866	25,474
Central nervous system | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	109,456	84,582
Central nervous system | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	66,276	60,139
License agreement | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	4,479	0
Cardiovascular system | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	45,878	32,503
Gastroenterology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,197	14,364
Oncology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	38,533	10,578
Metabolic disease / endocrine | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	11,185	9,265
Respiratory | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	11,136	12,815
Dermatology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,975	18,004
Other therapeutic classes | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,523	25,895
Other therapeutic classes | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	5,104	6,776
Distribution | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	109,713	83,230
Government label | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	34,952	24,516
Institutional | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	10,858	8,862
Other | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	$ 7,140	$ 5,448

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Contract Charge - Backs and Sales Volume Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	$ 559,334
Provision related to sales recorded in the period	885,322
Credits/payments issued during the period	(987,202)
Balance, end of period	457,454
Cash Discount Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	23,892
Provision related to sales recorded in the period	30,073
Credits/payments issued during the period	(26,550)
Balance, end of period	27,415
Accrued Returns Allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	136,486
Provision related to sales recorded in the period	16,220
Credits/payments issued during the period	(15,598)
Balance, end of period	137,108
Accrued Medicaid and Commercial Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	90,690
Provision related to sales recorded in the period	61,271
Credits/payments issued during the period	(55,250)
Balance, end of period	$ 96,711

Alliance and Collaboration - Ad

Alliance and Collaboration - Additional Information (Details) € in Millions, $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Feb. 26, 2024 USD ($)

Feb. 23, 2024 USD ($)

Feb. 23, 2024 EUR (€)

Jan. 24, 2024

Oct. 12, 2023 product

Dec. 28, 2022

May 07, 2018 USD ($)

Dec. 31, 2023 USD ($)

Mar. 31, 2024 USD ($)

Mar. 31, 2024 EUR (€)

Mar. 31, 2023 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Feb. 23, 2024 EUR (€)

Dec. 05, 2023 USD ($)

License Agreement with Orion Corporation

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement term

8 years

Collaborative arrangement renew for successive term

2 years

Collaborative arrangement license revenue agreement

$ 0.6

$ 0.6

License Agreement with Orion Corporation | Accounts Payable and Accrued Liabilities

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Deferred income

$ 7.8

10.7

$ 7.8

License Agreement with Orion Corporation | Other long-term liabilities

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Deferred income

4.7

1.2

4.7

ONGENTYS® License Agreement

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, medical and marketing activities

$ 6

Collaborative arrangement non-refundable license fee

$ 12.5

Collaborative arrangement non-refundable license fee, amortization period

8 years

License supply agreement, potential future milestone payments

$ 22.5

License Agreement with Zambon Biotech

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement term

15 years

15 years

Collaborative arrangement renew for successive term

2 years

2 years

License supply agreement, potential future milestone payments

$ 77.2

€ 71.5

Notice period

1 year

1 year

Nonrefundable license fee received, amount

$ 5.4

€ 5

Collaborative arrangement net revenue agreement

3.5

€ 3.2

Biosimilar Licensing and Supply Agreement

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

License supply agreement, potential future milestone payments

66

Other long term liabilities

$ 78.3

Collaborative arrangement maximum milestone paid

2.5

$ 26.5

Estimated useful life (in years)

7 years

Collaborative arrangement aggregate sales-based milestone payment

9.5

Collaborative arrangement, number of products | product

2

Collaborative arrangement upfront payment

$ 3

2.5

Biosimilar Licensing and Supply Agreement | Development Milestones

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

License supply agreement, potential future milestone payments

3.5

Biosimilar Licensing and Supply Agreement | Regulatory Approval

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

License supply agreement, potential future milestone payments

$ 15

Biosimilar Licensing and Supply Agreement | Achievement of Cumulative Net Sales

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

License supply agreement, potential future milestone payments

$ 47.5

Knight Therapeutics International S.A. License Agreement

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement term

15 years

Collaborative arrangement renew for successive term

2 years

License supply agreement, potential future milestone payments

$ 10.5

Notice period

1 year

Nonrefundable license fee received, amount

$ 1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) $ in Thousands		3 Months Ended		10 Months Ended	12 Months Ended
	Nov. 07, 2023	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Nov. 06, 2023	Dec. 31, 2019 USD ($)	Dec. 31, 2018	Dec. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Income tax expense (benefit)		$ 6,156	$ 668
Effective tax rate (percent)		(8.20%)	(7.10%)
Valuation allowance		$ 566,000					$ 566,500
Tax receivable agreement, payment ratio						0.01
Percentage of tax receivable agreement paid to other holders of Amneal common units (percent)	75%			85%		85%
Reversal of accrued tax receivable agreement liability					$ 192,800
Liabilities recorded under tax receivable agreement		185,000					185,000
Tax receivable agreement liability		5,700					$ 3,800
Increase in tax receivable agreement liability		$ 1,948	$ 826

Loss per Share - Computation of

Loss per Share - Computation of Basic and Diluted Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss attributable to Amneal Pharmaceuticals, Inc.	$ (91,643)	$ (6,943)
Denominator:
Weighted-average shares outstanding - basic (in shares)	307,279	152,109
Weighted-average shares outstanding - diluted (in shares)	307,279	152,109
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic (in dollars per share)	$ (0.30)	$ (0.05)
Diluted (in dollars per share)	$ (0.30)	$ (0.05)

Loss per Share - Securities Exc

Loss per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Shares of Old PubCo Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	0	152,117
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	2,406	2,632
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	10,837	11,576
Performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	7,827	7,018

Trade Accounts Receivable, Ne_2

Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Gross accounts receivable	$ 1,156,861	$ 1,199,980
Allowance for credit losses	(3,037)	(3,022)
Contract charge-backs and sales volume allowances	(457,454)	(559,334)
Cash discount allowances	(27,415)	(23,892)
Subtotal	(487,906)	(586,248)
Nonrelated Party
Related Party Transaction [Line Items]
Trade accounts receivable, net	$ 668,955	$ 613,732

Trade Accounts Receivable, Ne_3

Trade Accounts Receivable, Net - Concentration of Receivables (Details) - Customer Concentration Risk - Accounts Receivable	3 Months Ended	6 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	32%	40%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	29%	24%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	23%	22%

Inventories - Components of Inv

Inventories - Components of Inventories, Net of Reserves (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 196,737	$ 217,744
Work in process	57,924	59,563
Finished goods	315,992	304,077
Total inventories	$ 570,653	$ 581,384

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deposits and advances	$ 1,935	$ 2,200
Prepaid insurance	4,780	8,334
Prepaid regulatory fees	4,219	6,331
Income and other tax receivables	12,198	13,168
Prepaid taxes	9,205	11,899
Prepaid taxes	12,802	9,929
Chargebacks receivable	8,575	7,876
Other prepaid assets	33,584	22,948
Total prepaid expenses and other current assets	$ 87,298	$ 82,685

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Goodwill [Roll Forward]
Balance, beginning of period	$ 598,629	$ 598,853
Currency translation	(80)	$ (224)
Balance, end of period	$ 598,549

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Goodwill	$ 598,549,000		$ 598,629,000	$ 598,853,000
Amortization of intangible assets	39,900,000	$ 41,100,000
Intangible asset impairment charges, indefinite-lived	0	$ 0
Specialty
Goodwill [Line Items]
Goodwill	366,300,000		366,300,000
Generics
Goodwill [Line Items]
Goodwill	162,700,000		162,800,000
AvKARE
Goodwill [Line Items]
Goodwill	$ 69,500,000		$ 69,500,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,319,269	$ 1,310,771
Accumulated Amortization	(815,842)	(776,193)
Net	503,427	534,578
In-process research and development	355,845	355,845
Intangible assets, cost	1,675,114	1,666,616
Intangible assets, net	$ 859,272	890,423
Product rights
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period (in years)	6 years 2 months 12 days
Cost	$ 1,207,469	1,198,971
Accumulated Amortization	(739,351)	(703,297)
Net	$ 468,118	495,674
Other intangible assets
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period (in years)	3 years 1 month 6 days
Cost	$ 111,800	111,800
Accumulated Amortization	(76,491)	(72,896)
Net	$ 35,309	$ 38,904

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2023	$ 119,432
2025	121,638
2026	73,115
2027	52,606
2028	33,263
2029	26,484
Thereafter	76,889
Net	$ 503,427	$ 534,578

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Other Assets [Line Items]
Other assets	$ 73,747	$ 55,517
Interest rate swap
Other Assets [Line Items]
Other assets	52,632	37,089
Security deposits
Other Assets [Line Items]
Other assets	3,616	3,602
Long-term prepaid expenses
Other Assets [Line Items]
Other assets	3,099	3,273
Deferred revolving credit facility costs
Other Assets [Line Items]
Other assets	4,007	4,427
Other long term assets
Other Assets [Line Items]
Other assets	$ 10,393	$ 7,126

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Accounts payable	$ 175,325	$ 143,572
Accrued returns allowance	137,108	136,486
Accrued compensation	44,806	71,122
Accrued Medicaid and commercial rebates	96,711	90,690
Accrued royalties	19,779	23,342
Commercial chargebacks and rebates	10,226	10,226
Accrued professional fees	14,598	11,005
Accrued other	59,965	48,219
Nonrelated Party
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	$ 558,518	$ 534,662

Debt - Summary of Long-term Deb

Debt - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt	$ 2,528,928	$ 2,543,626
Less: debt issuance costs	(117,561)	(123,497)
Total debt, net of debt issuance costs	2,411,367	2,420,129
Less: current portion of long-term debt	(33,660)	(34,125)
Total long-term debt, net	2,377,707	2,386,004
Term Loan Due May 2025
Debt Instrument [Line Items]
Total debt	191,979	191,979
Term Loan Due May 2028
Debt Instrument [Line Items]
Total debt	$ 2,336,949	$ 2,351,647

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Borrowings on revolving credit facilities	$ 48,000	$ 80,000
Amended New Revolving Credit Facility
Debt Instrument [Line Items]
Borrowings on revolving credit facilities	20,000
Repayment of outstanding principal	20,000
Revolving credit facility			$ 179,000
Amended Rondo Credit Facility
Debt Instrument [Line Items]
Borrowings on revolving credit facilities	28,000
Repayment of outstanding principal	28,000
Revolving credit facility	$ 179,000

Other Long-Term Liabilities (De

Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Nonrelated Party
Other Liabilities [Line Items]
Other long-term liabilities	$ 24,579	$ 29,679
Uncertain tax positions
Other Liabilities [Line Items]
Other long-term liabilities	504	497
Long-term compensation
Other Liabilities [Line Items]
Other long-term liabilities	18,073	21,283
Contingent Consideration
Other Liabilities [Line Items]
Other long-term liabilities	433	433
Other long-term liabilities
Other Liabilities [Line Items]
Other long-term liabilities	$ 5,569	$ 7,466

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Interest rate swap	$ 52,632	$ 37,089
Liabilities
Deferred compensation plan liabilities	9,668	9,100
Contingent consideration liabilities	1,021	921
Quoted Prices in Active Markets (Level 1)
Assets
Interest rate swap	0	0
Liabilities
Deferred compensation plan liabilities	0	0
Contingent consideration liabilities	0	0
Significant Other Observable Inputs (Level 2)
Assets
Interest rate swap	52,632	37,089
Liabilities
Deferred compensation plan liabilities	9,668	9,100
Contingent consideration liabilities	0	0
Significant Unobservable Inputs (Level 3)
Assets
Interest rate swap	0	0
Liabilities
Deferred compensation plan liabilities	0	0
Contingent consideration liabilities	$ 1,021	$ 921

Fair Value Measurements - Summa

Fair Value Measurements - Summary of the Company’s Indebtedness at Fair Value (Details) - Significant Other Observable Inputs (Level 2) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Senior Secured Credit Facility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt fair value		$ 2,328,130
Sellers Notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt fair value	$ 41,944	41,033
Term Loan Due 2025 | Senior Secured Credit Facility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt fair value	192,099	$ 190,779
Term Loan Due 2028 | Senior Secured Credit Facility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt fair value	$ 2,339,870

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) - USD ($)		3 Months Ended
	Nov. 14, 2023	Mar. 31, 2024	Dec. 31, 2023	Oct. 31, 2019
Derivative [Line Items]
Interest rate swap		$ 52,632,000	$ 37,089,000
Derivative gain reclassified from accumulated OCI into income (loss)		6,500,000
Cash flow hedge gain (loss) to be reclassified within 12 months		26,100,000
Net of income taxes, recognized in accumulated other comprehensive income		$ 42,800,000
Interest Rate Lock Agreement
Derivative [Line Items]
Notional amount				$ 1,300,000,000
November 2023 Swap
Derivative [Line Items]
Notional amount	$ 1,300,000,000
Derivative, fixed interest rate	2.7877%
Interest rate swap	$ 66,700,000
Amended October 2019 Swap
Derivative [Line Items]
Derivative, fixed interest rate	1.366%
Unrealized gain recorded within accumulated other comprehensive income (loss)	$ 66,700,000

Financial Instruments - Summary

Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Variable to Fixed Interest Rate Swap | Designated as Hedging Instrument | Other Assets
Derivative [Line Items]
Fair Value	$ 52,632	$ 37,089

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands

1 Months Ended

3 Months Ended

May 02, 2024

Apr. 30, 2024 USD ($) $ / twinPack

Feb. 28, 2024

Dec. 18, 2023 USD ($)

May 31, 2023 case

Feb. 28, 2023 USD ($)

Jun. 10, 2020 state action

Mar. 13, 2015 medication

Nov. 06, 2014 representative

Dec. 31, 2023 USD ($) case state

Mar. 31, 2024 USD ($)

Mar. 31, 2023 USD ($)

May 15, 2023

Nov. 01, 2019 state

May 10, 2019 state

Loss Contingencies [Line Items]

(Credit) charges related to legal matters, net

$ (94,359)

$ 436

Liabilities for legal matters - long term

$ 316

85,479

Opana ER® antitrust litigation

Loss Contingencies [Line Items]

(Credit) charges related to legal matters, net

$ 436

Loss contingency accrual

$ 50,000

$ 265,000

Litigation settlement, interest rate

3%

United States Department of Justice Investigations

Loss Contingencies [Line Items]

Number of sales representatives | representative

1

Number of generic prescription medications | medication

4

Percentage Of Prescribed Label

1%

Generic Digoxin and Doxycycline Antitrust Litigation

Loss Contingencies [Line Items]

Number of states, filed civil lawsuit | state

46

43

Loss contingency civil lawsuit filed number of additional states | state

9

Number of actions | action

2

Civil prescription opioid litigation

Loss Contingencies [Line Items]

(Credit) charges related to legal matters, net

$ (94,400)

Number of cases filed | case

900

Number of states with cases | state

7

Number of claims dismissed | case

2

Liabilities for legal matters - long term

$ 300

85,500

Estimated litigation liability

$ 21,500

$ 115,600

Civil prescription opioid litigation | Subsequent Event

Loss Contingencies [Line Items]

Litigation settlement agreement terms

10 years

Civil prescription opioid litigation | Litigation Settlement, Option One | Subsequent Event

Loss Contingencies [Line Items]

Litigation settlement amount

$ 92,500

Litigation settlement, product supply amount

$ 180,000

Litigation settlement, product supply price (in USD per twin pack) | $ / twinPack

125

Civil prescription opioid litigation | Litigation Settlement, Option One | Subsequent Event | Maximum

Loss Contingencies [Line Items]

Litigation settlement amount

$ 137,500

Civil prescription opioid litigation | Litigation Settlement, Option Two | Subsequent Event

Loss Contingencies [Line Items]

Litigation settlement agreement terms

4 years

Litigation settlement amount

$ 45,000

Litigation settlement, percentage of product value

25%

Ranitidine Litigation

Loss Contingencies [Line Items]

Number of states with cases | state

5

Metformin Litigation | Litigation Settlement, Option One | Subsequent Event

Loss Contingencies [Line Items]

Deadline period for defendants

3 days

Metformin Litigation | Litigation Settlement, Option Two | Subsequent Event

Loss Contingencies [Line Items]

Deadline period for defendants

30 days

Xyrem® (Sodium Oxybate) Antitrust Litigation

Loss Contingencies [Line Items]

Litigation settlement amount

$ 4,000

$ 1,900

Litigation settlement expense

$ 3,000

Estimated litigation liability

$ 2,000

UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.

Loss Contingencies [Line Items]

Deadline period for defendants

45 days

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	$ 30,130	$ 76,988
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	0	50,000
Opana ER® antitrust litigation-accrued interest
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	0	2,347
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	30,130	21,189
Civil prescription opioid litigation (Liabilities for legal matters - long term)	85,479	316
Other
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	$ 0	$ 3,452

Stockholders' Equity and Redeem

Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Nov. 07, 2023	Dec. 31, 2021	Apr. 02, 2021	Jan. 31, 2020
Class of Stock [Line Items]
Tax distribution		$ 26.8
Common Class B
Class of Stock [Line Items]
Common stock, shares outstanding (in shares)			0
Amneal Pharmaceuticals, LLC
Class of Stock [Line Items]
Ownership by parent (percent)	100%		100%
Kashiv Specialty Pharmaceuticals, LLC
Class of Stock [Line Items]
Voting interest acquired (percent)					98%
Kashiv Specialty Pharmaceuticals, LLC | Sellers of KSP
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)					2%
Av Kare Incorporation And R And S Northeast L L C
Class of Stock [Line Items]
Voting interest acquired (percent)				65.10%
Tax distribution recorded as a reduction to redeemable non-controlling interest	$ 4.4	$ 3
Av Kare Incorporation And R And S Northeast L L C | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)	34.90%					34.90%

Stockholders' Equity and Rede_2

Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	$ 20,011	$ 183,979
Stockholders' equity ending balance	(63,629)	134,668
Reclassification of cash flow hedge to earnings, net of tax	0	0
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(66,072)	(32,382)
Other comprehensive loss before reclassification	(390)	898
Reallocation of ownership interests		(195)
Reclassification of cash flow hedge to earnings, net of tax of $0	0
Stockholders' equity ending balance	(66,462)	(31,679)
Unrealized gain (loss) on cash flow hedge, net of tax
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	33,723	42,321
Other comprehensive loss before reclassification	15,543	(7,135)
Reallocation of ownership interests		257
Reclassification of cash flow hedge to earnings, net of tax of $0	(6,515)
Stockholders' equity ending balance	42,751	35,443
Accumulated other comprehensive (loss) income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(32,349)	9,939
Other comprehensive loss before reclassification	15,153	(6,237)
Reallocation of ownership interests		62
Reclassification of cash flow hedge to earnings, net of tax of $0	(6,515)
Stockholders' equity ending balance	$ (23,711)	$ 3,764

Related Party Transactions - Re

Related Party Transactions - Related Party Agreements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Trade accounts receivable, net	$ 78		$ 0
Rondo Class B unit holders - tax distributions
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	3,777		0
Research and development - Parking Space Lease | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	25	$ 17
Research and Development - Development and Commercialization Agreement - Ganirelix Acetate and Centrorelix Acetate | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	50
Cost of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	4,526	144
Research and Development Storage Income | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	(77)	(48)
Inventory and Cost of Goods Sold | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,216	0
Inventory and Cost of Goods Sold | Kanan, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	592	566
Inventory and Cost of Goods Sold | Sutaria Family Realty, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	314	305
Inventory and Cost of Goods Sold | Apace Packaging, LLC - packaging agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	5,001	1,836
Inventory and Cost of Goods Sold | AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	2,312	575
Inventory and Cost of Goods Sold | Alkermes
Related Party Transaction [Line Items]
Amounts of transaction with related party	12	2
Research and Development - Generic Development Supply Agreement - Research and Development Material | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	(48)	0
Deferred Revenue - Generic Development Supply Agreement - Development Activity Deferred Income | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	(422)	0
Research and Development
Related Party Transaction [Line Items]
Amounts of transaction with related party	500	0
Research and Development | Avtar Investments LLC - consulting services
Related Party Transaction [Line Items]
Amounts of transaction with related party	69	188
Selling, General and Administrative - Operating Lease | Tracy Properties LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	143	169
Selling, General and Administrative - Operating Lease | AvPROP, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	44	47
Selling, General and Administrative - Logistics Services | R&S Solutions - logistics services
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	20
Other Expense | Members - tax receivable agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,948	$ 826
Related Party
Related Party Transaction [Line Items]
Trade accounts receivable, net	1,521		955
Accounts payable and accrued expenses	17,075		7,321
Other long-term liabilities	11,394		11,776
Related Party | Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Trade accounts receivable, net	1,434		954
Accounts payable and accrued expenses	5,773		3,179
Other long-term liabilities	530		430
Related Party | Apace Packaging, LLC - packaging agreement
Related Party Transaction [Line Items]
Trade accounts receivable, net	9		0
Accounts payable and accrued expenses	1,863		1,091
Related Party | AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	1,650		1,958
Related Party | Avtar Investments LLC - consulting services
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	22		100
Related Party | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	442		442
Related Party | Alkermes Plc
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	16		2
Related Party | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
Related Party Transaction [Line Items]
Other long-term liabilities	8,691		8,139
Related Party | Alkermes
Related Party Transaction [Line Items]
Trade accounts receivable, net	0		1
Related Party | Members - tax receivable agreement
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	3,532		549
Other long-term liabilities	$ 2,173		$ 3,207

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Mar. 31, 2024	Dec. 31, 2022	Mar. 31, 2024
Kashiv Bio Sciences License and Commercialization Agreement
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment			$ 0.5
Collaborative arrangement aggregate sales-based milestone payment	$ 37.5
Collaborative arrangement, profit share (percent)	50%
Collaborative arrangement term			10 years
Kashiv Bio Sciences License and Commercialization Agreement | Development Milestones
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments	$ 7
Kashiv Bio Sciences License and Commercialization Agreement | Regulatory Approval
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments	$ 7.5
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party		$ 2.4
Ownership interest (percent)	50%		50%
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Development Milestones
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			$ 10
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Regulatory Approval
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			20
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Achievement Of Annual Commercial Milestone
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			5
R&D Reimbursement | Related Party | Kashiv Bio Sciences License and Commercialization Agreement | Initial Commercial Launch Milestones
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			20
Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment	$ 14.5
Kashiv Biosciences LLC | R&D Reimbursement | Related Party | Maximum
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments			$ 35

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024 segment product
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Number of products families | product	270

Segment Information - Schedules

Segment Information - Schedules of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Net revenue	$ 659,191	$ 557,540
Cost of goods sold	421,131	379,354
Gross profit	238,060	178,186
Selling, general and administrative	112,595	102,096
Research and development	39,298	38,690
Intellectual property legal development expenses	984	1,644
Restructuring and other charges	1,470	510
Change in fair value during the period	100	2,457
(Credit) charges related to legal matters, net	94,359	(436)
Other operating income	0	(1,224)
Operating (loss) income	(10,746)	34,449
Generics
Segment Reporting Information [Line Items]
Net revenue	391,294	343,806
AvKARE
Segment Reporting Information [Line Items]
Net revenue	162,663	122,056
Operating Segments | Generics
Segment Reporting Information [Line Items]
Net revenue	391,294	343,806
Cost of goods sold	239,922	230,551
Gross profit	151,372	113,255
Selling, general and administrative	33,085	27,600
Research and development	34,371	32,359
Intellectual property legal development expenses	960	1,624
Restructuring and other charges	0	99
Change in fair value during the period	0	0
(Credit) charges related to legal matters, net	94,359	(2,444)
Other operating income		(1,224)
Operating (loss) income	(11,403)	55,241
Operating Segments | Specialty
Segment Reporting Information [Line Items]
Net revenue	105,234	91,678
Cost of goods sold	44,800	43,191
Gross profit	60,434	48,487
Selling, general and administrative	25,196	22,379
Research and development	4,927	6,331
Intellectual property legal development expenses	24	20
Restructuring and other charges	946	0
Change in fair value during the period	100	2,457
(Credit) charges related to legal matters, net	0	0
Other operating income		0
Operating (loss) income	29,241	17,300
Operating Segments | AvKARE
Segment Reporting Information [Line Items]
Net revenue	162,663	122,056
Cost of goods sold	136,409	105,612
Gross profit	26,254	16,444
Selling, general and administrative	14,907	12,940
Research and development	0	0
Intellectual property legal development expenses	0	0
Restructuring and other charges	0	0
Change in fair value during the period	0	0
(Credit) charges related to legal matters, net	0	0
Other operating income		0
Operating (loss) income	11,347	3,504
Corporate and Other
Segment Reporting Information [Line Items]
Net revenue	0	0
Cost of goods sold	0	0
Gross profit	0	0
Selling, general and administrative	39,407	39,177
Research and development	0	0
Intellectual property legal development expenses	0	0
Restructuring and other charges	524	411
Change in fair value during the period	0	0
(Credit) charges related to legal matters, net	0	2,008
Other operating income		0
Operating (loss) income	$ (39,931)	$ (41,596)

Subsequent Events (Details)

Subsequent Events (Details) - Apr. 30, 2024 - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Subsidiary In India - Subsequent Event ₨ in Millions, $ in Millions	INR (₨)	USD ($)	USD ($)
Subsequent Event [Line Items]
Consideration on sale of subsidiary	₨ 1,000		$ 12
Proceeds from divestiture of businesses	416	$ 5
Assumption of loan payable	₨ 600	$ 7
Loan payable, interest rate	11%		11%